ストックスクリーナーアプリを入手
7.8669
2.72%
-0.2331
前日終値:
$8.10
開ける：
$8
24時間の取引高:
689.16K
Relative Volume:
0.93
時価総額：
$5.36B
収益：
$8.51B
当期純損益:
$568.12M
株価収益率:
11.67
EPS:
0.6739
ネットキャッシュフロー:
$706.97M
1週間 パフォーマンス:
-4.25%
1か月 パフォーマンス:
-4.02%
6か月 パフォーマンス:
-9.74%
1年 パフォーマンス:
+10.98%
1日の値動き範囲:
$7.7301
$8.08
1週間の範囲:
$7.7301
$8.465
52週間の値動き範囲:
$7.10
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.87 | 5.51B | 8.51B | 568.12M | 706.97M | 0.6739 |
LLY
Lilly Eli Co
|
966.85 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
220.63 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
202.63 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
181.79 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
144.82 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | 再開されました | Morgan Stanley | Overweight |
| 2024-03-12 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-04-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | アップグレード | Barclays | Underweight → Equal Weight |
| 2023-01-18 | アップグレード | Jefferies | Hold → Buy |
| 2022-04-08 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-10-19 | ダウングレード | Barclays | Overweight → Underweight |
| 2021-10-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-06-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 開始されました | Deutsche Bank | Hold |
| 2021-03-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | アップグレード | HSBC Securities | Hold → Buy |
| 2020-10-01 | アップグレード | Citigroup | Sell → Neutral |
| 2020-06-09 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-06-09 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-03-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-06-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-02-08 | ダウングレード | Berenberg | Buy → Hold |
| 2018-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2018-06-01 | 開始されました | Barclays | Overweight |
| 2017-10-31 | 開始されました | Citigroup | Buy |
| 2017-06-30 | ダウングレード | Goldman | Buy → Neutral |
| 2017-04-06 | 開始されました | BofA/Merrill | Buy |
| 2017-01-03 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-02-09 | アップグレード | Berenberg | Hold → Buy |
| 2016-01-04 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | ダウングレード | HSBC Securities | Buy → Hold |
| 2015-11-20 | ダウングレード | Berenberg | Buy → Hold |
| 2015-04-28 | ダウングレード | Berenberg | Buy → Hold |
すべてを表示
Grifols Sa Adr (GRFS) 最新ニュース
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
GRFS Stock Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada
Grifols falls 6% after skipping 2026 revenue target; €7.52 bln sales - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again - GlobeNewswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
San Gabriel Valley Tribune - FinancialContent
Cramer 'Takes A Pass' On Stock That's Down 31% Over Past 6 Months: 'Don't Want To Go Against Musk' - Sahm
Grifols Sa Adr (GRFS) 財務データ
収益
当期純利益
現金流量
EPS
0.92%
2.04%
大文字化:
|
ボリューム (24 時間):